Chimeric Therapeutics Ltd (ASX:CHM) is rapidly accelerating the development of its chlorotoxin CAR T therapy (CLTX CAR T) cell therapy as it looks for additional therapies to bring into its pipeline.
The clinical-stage biotech company is looking at more curative therapies for patients with cancer, and not just therapies that delay disease progression.
Chimeric Therapeutics chief operating officer Jennifer Chow said: “The company is now focused on its pipeline because we do believe that by building out a bigger pipeline or a stronger pipeline with additional assets that have the same type of promise to patients, we re actually going to be able to help more patients in the long term.”
Chimeric Therapeutics has CLTX CAR T abstract accepted for prestigious annual meeting of American Society of Clinical Oncology
CHM has exclusive global rights to IP covering the Chlorotoxin CAR T which is in development for patients with recurrent glioblastoma and is also being investigated for development in patients with other solid tumours such as melanoma, small cell lung cancer, prostate cancer and colorectal cancer. Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.
Chimeric Therapeutics Ltd (ASX:CHM) has had the first CLTX CAR T abstract accepted for presentation at the prestigious annual meeting of the American Society of Clinical Oncology (ASCO), which is being virtually held from June 4-8.
The company is the only ASX-listed biotech conducting clinical trials in CAR-T technology and is focused on Phase 1 clinical trials for its CLTX-CAR T.